Rare Kidney Diseases Market Report 2026

Rare Kidney Diseases Market Overview

• Rare Kidney Diseases market size has reached to $3.03 billion in 2025 • Expected to grow to $4.88 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Government Catalysts Fueling Rare Kidney Disease Market Surge • Market Trend: Pioneering Non-Immunosuppressive Therapies Revolutionize Rare Kidney Disease Treatment Landscape • North America was the largest region in 2025.

What Is Covered Under Rare Kidney Diseases Market?

Rare kidney disease is a condition where kidneys are not functioning correctly, waste accumulates in the body, and causes problems with your health. It is a set of renal diseases that have a low frequency in the general population, and these disorders frequently have a genetic or hereditary origin. The main target indications of rare kidney diseases are IgA nephropathy, lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy, C3 glomerulopathy, and others. IgA nephropathy is a kidney disease in which antibodies (named IgA) accumulate in kidney tissue causing inflammation, where angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are used to lower patients' blood pressure and reduce protein loss for slowing the progression of kidney damage, managing symptoms, and preventing complications. The various types of molecules involved are small molecules and biologics that are administered by various routes of administration such as oral, intravenous, subcutaneous, and others.

What Is The Rare Kidney Diseases Market Growth Forecast?

The rare kidney diseases market size is expected to see rapid growth in the next few years. It will grow to $4.88 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advances in genomics-based drug discovery, rising orphan drug approvals, increasing investment in rare disease research, growing use of personalized medicine approaches, expanding pipeline of complement and immune-targeted therapies. Major trends in the forecast period include rising focus on targeted therapies for rare renal disorders, increasing clinical trial activity for orphan kidney drugs, growing adoption of biologics in immune-mediated kidney diseases, expansion of companion diagnostics for early disease detection, increasing regulatory incentives for rare disease drug development.

Global Rare Kidney Diseases Market Segmentation

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications 2) By Type Of Molecule: Small Molecules, Biologics 3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration Subsegments: 1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management 2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics 3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents 4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies 5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies 6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

What Is The Driver Of The Rare Kidney Diseases Market?

The increasing prevalence of chronic kidney disease (CKD) is significantly contributing to the rare kidney disease market. Chronic kidney disease refers to a disorder where the kidneys are damaged and are unable to properly filter blood. The increased prevalence of chronic kidney diseases will increase the chances of the development of rare kidney diseases in patients, which will increase the demand for the therapeutics required for rare kidney diseases For instance, in August 2025, according to the National Kidney Foundation, Inc., a US-based voluntary nonprofit health organization, the Senate has approved a $5 million increase in the FY 2026 Labor, Health and Human Services, and Education appropriations bill to support kidney transplant reform and early detection efforts. This boost brings total funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative to $59 million. Therefore, the increasing prevalence of chronic kidney disease (CKD) will drive the rare kidney disease industry.

Key Players In The Global Rare Kidney Diseases Market

Major companies operating in the rare kidney diseases market are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc.

Global Rare Kidney Diseases Market Trends and Insights

Major companies operating in the rare kidney diseases market are focusing on developing non-immunosuppressive therapy for treating rare kidney diseases. Non-immunosuppressive therapy is a unique treatment that can treat patients with progressive kidney diseases, which is not possible for regular therapies used for treating rare kidney diseases. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched sparsentan, which is commercially known as Filspari. the drug is the first non-immunosuppressive therapy approved for primary immunoglobulin A nephropathy (IgAN). With a distinct mode of action, Filspari functions by obstructing angiotensin and endothelin receptors. This characteristic sets Filspari apart from angiotensin-targeting ACE inhibitors and ARBs, well-known medications primarily prescribed to treat hypertension that have been repurposed for the treatment of IgAN due to their capacity to lower blood pressure in the kidney.

What Are Latest Mergers And Acquisitions In The Rare Kidney Diseases Market?

In February 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca Pharmaceuticals LP aims to strengthen its portfolio in chronic renal illness and uncontrolled hypertension. CinCor Inc. is a US-based clinical-stage biopharmaceutical company that offers medication for rare kidney diseases.

Regional Insights

North America was the leading region in the rare kidney disease market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rare Kidney Diseases Market?

The rare kidney disease market includes revenues earned by entities by providing services clinical evaluation, genetic counseling, genetic screening, specific testing, molecular diagnosis, hemodialysis, and peritoneal dialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rare Kidney Diseases Market Report 2026?

The rare kidney diseases market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rare kidney diseases industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.